E63 Cardiovascular risk is increased in patients with calcium oxalate urolithiasis and correlated with urinary oxalate excretion

Abstract

INTRODUCTION AND OBJECTIVES: There is a strong correlation between the development of urolithiasis and metabolic syndrome(MS) that is characterized with an increase in cardiovascular disease risk. Endothelial dysfunction (ED) is a well-known indicator of cardiovascular risk. Increase in systemic ADMA levelsan indicator of ED was reported in urolithiasis in our previous animal study. The aim of this study was to assess the cardiovascular risk in patients with urolithiasis. METHODS: One hundred patients with calcium oxalate urolithiasis and 100 healthy age-matched subjects as a control group were included into this study. Framingham risk score was used for the assessment of 10-year cardiovascular risk and SCORE risk scale for 10-year fatal cardiovascular risk assessment. Oxalate, calcium, citrate, uric acid and creatinine in 24-hour urine samples were used as stone development risk factors. RESULTS: Mean Framingham risk score was 10,26 9,05 (14,55 9,30 in men and 6,32 8,7 in women). It was 4,39 5,11 in healthy controls (p 0,0001). The odds-ratio for the development of cardiovascular disease was 5,18 (95% CI, 2,57–10,31) and 10 year fatal cardiovascular risk was 1,52 2,75 in patients with urolithiasis. Framingham risk score was found to be correlated with urinary oxalate excretion (p 0,002, r 0,373). Urinary oxalate excretion was also correlated with systolic blood pressure (p 0,0001, r 0,444), total cholesterol (p 0,01, r 0,293) and fasting blood glucose (p 0,007, r 0,456). CONCLUSIONS: This is the first study pointing out an increased cardivascular risk in patients with calcium oxalate urolithiasis in correlation with urinary stone risk factors. Further large populationbased prospective studies are needed for the confirmation.